New Predictor of Atherosclerosis in Subjects With COPD: Atherogenic Indices

References

1. 1.↵
   The Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2016. http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/. Accessed March 9, 2016.
2. 2.↵
   1. Fabbri LM,
   2. Luppi F,
   3. Beghé B,
   4. Rabe KF

   . Complex chronic comorbidities of COPD. Eur Respir J 2008;31(1):204–212.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Roversi S,
   2. Roversi P,
   3. Spadafora G,
   4. Rossi R,
   5. Fabbri LM

   . Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Invest 2014;44(1):93–102.

   OpenUrlPubMed
4. 4.↵
   1. Corbi G,
   2. Bianco A,
   3. Turchiarelli V,
   4. Cellurale M,
   5. Fatica F,
   6. Daniele A,
   7. et al

   . Potential mechanisms linking atherosclerosis and increased cardiovascular risk in COPD: focus on sirtuins. Int J Mol Sci 2013;14(6):12696–12713.

   OpenUrlPubMed
5. 5.↵
   1. Bellocchia M,
   2. Masoero M,
   3. Ciuffreda A,
   4. Croce S,
   5. Vaudano A,
   6. Torchio R,
   7. et al

   . Predictors of cardiovascular disease in asthma and chronic obstructive pulmonary disease. Multidiscip Respir Med 2013;8(1):58.

   OpenUrlPubMed
6. 6.↵
   1. Nussbaumer-Ochsner Y,
   2. Rabe KF

   . Systemic manifestations of COPD. Chest 2011;139(1):165–173.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Acay A,
   2. Ulu MS,
   3. Ahsen A,
   4. Ozkececi G,
   5. Demir K,
   6. Ozuguz U,
   7. et al

   . Atherogenic index as a predictor of atherosclerosis in subjects with familial Mediterranean fever. Medicina 2014;50(6):329–333.

   OpenUrl
8. 8.
   1. Caminhotto Rde O,
   2. da Fonseca FL,
   3. de Castro NC,
   4. Arantes JP,
   5. Sertié RA

   . Atkins diet program rapidly decreases atherogenic index of plasma in trained adapted overweight men. Arch Endocrinol Metab 2015;59(6):568–571.

   OpenUrlPubMed
9. 9.↵
   1. Singh M,
   2. Pathak MS,
   3. Paul A

   . A study on atherogenic indices of pregnancy induced hypertension patients as compared to normal pregnant women. J Clin Diagn Res 2015;9(7):BC05–BC08.

   OpenUrl
10. 10.
    1. Bakry OA,
    2. El Farargy SM,
    3. Ghanayem N,
    4. Soliman A

    . Atherogenic index of plasma in non-obese women with androgenetic alopecia. Int J Dermatol 2015;54(9):e339–e344.

    OpenUrlPubMed
11. 11.
    1. Akbas EM,
    2. Timuroglu A,
    3. Ozcicek A,
    4. Ozcicek F,
    5. Demirtas L,
    6. Gungor A,
    7. Akbas N

    . Association of uric acid, atherogenic index of plasma and albuminuria in diabetes mellitus. Int J Clin Exp Med 2014;7(12):5737–5743.

    OpenUrlPubMed
12. 12.↵
    1. Nunes SO,
    2. Piccoli de Melo LG,
    3. Pizzo de Castro MR,
    4. Barbosa DS,
    5. Vargas HO,
    6. Berk M,
    7. Maes M

    . Atherogenic index of plasma and atherogenic coefficient are increased in major depression and bipolar disorder, especially when comorbid with tobacco use disorder. J Affect Disord 2015;172:55–62.

    OpenUrlPubMed
13. 13.↵
    1. Millán J,
    2. Pintó X,
    3. Muñoz A,
    4. Zúñiga M,
    5. Rubiés-Prat J,
    6. Pallardo LF,
    7. et al

    . Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 2009;5:757–765.

    OpenUrlPubMed
14. 14.↵
    1. Essiarab F,
    2. Taki H,
    3. Lebrazi H,
    4. Sabri M,
    5. Saïle R

    . Usefulness of lipid ratios and atherogenic index of plasma in obese Moroccan women with or without metabolic syndrome. Ethn Dis 2014;24(2):207–212.

    OpenUrlPubMed
15. 15.↵
    1. Celli BR,
    2. MacNee W

    , ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23(6):932–946.

    OpenUrlFREE Full Text
16. 16.↵
    1. Dobiášová M

    . Calculator of atherogenic risk. http://www.biomed.cas.cz/fgu/aip/calculator.php. Accessed February 1, 2016.
17. 17.↵
    1. Schnell K,
    2. Weiss CO,
    3. Lee T,
    4. Krishnan JA,
    5. Leff B,
    6. Wolff JL,
    7. Boyd C

    . The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med 2012;12:26.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Iwamoto H,
    2. Yokoyama A,
    3. Kitahara Y,
    4. Ishikawa N,
    5. Haruta Y,
    6. Yamane K,
    7. et al

    . Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 2009;179(1):35–40.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Müllerova H,
    2. Agusti A,
    3. Erqou S,
    4. Mapel DW

    . Cardiovascular comorbidity in chronic obstructive pulmonary disease: systematic literature review. Chest 2013;144(4):1163–1178.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Eriksson B,
    2. Lindberg A,
    3. Müllerova H,
    4. Rönmark E,
    5. Lundbäck B

    . Association of heart diseases with COPD and restrictive lung function: results from a population survey. Respir Med 2013;107(1):98–106.

    OpenUrlPubMed
21. 21.↵
    1. Ridker PM,
    2. Bassuk SS,
    3. Toth PP

    . C-reactive protein and risk of cardiovascular disease: Evidence and clinical application. Curr Atheroscler Rep 2003;5(5):341–349.

    OpenUrlCrossRefPubMed
22. 22.
    1. Hancox RJ,
    2. Poulton R,
    3. Greene JM,
    4. Filsell S,
    5. McLachlan CR,
    6. Rasmussen F,
    7. et al

    . Systemic inflammation and lung function in young adults. Thorax 2007;62(12):1064–1068.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Günay E,
    2. Sarınç Ulaşlı S,
    3. Akar O,
    4. Ahsen A,
    5. Günay S,
    6. Koyuncu T,
    7. Unlü M

    . Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. Inflammation 2014;37(2):374–380.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Esteve E,
    2. Ricart W,
    3. Fernández-Real JM

    . Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 2005;24(1):16–31.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Dobiásová M,
    2. Frohlich J

    . The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 2001;34(7):583–588.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Bortolasci CC,
    2. Vargas HO,
    3. Vargas Nunes SO,
    4. de Melo LG,
    5. de Castro MR,
    6. Moreira EG,
    7. et al

    . Factors influencing insulin resistance in relation to atherogenicity in mood disorders, the metabolic syndrome and tobacco use disorder. J Affect Disord 2015;179:148–155.

    OpenUrlPubMed
27. 27.↵
    1. Tautu OF,
    2. Darabont R,
    3. Onciul S,
    4. Deaconu A,
    5. Comanescu I,
    6. Andrei RD,
    7. et al

    . New cardiovascular risk factors and their use for an accurate cardiovascular risk assessment in hypertensive patients. Maedica 2014;9(2):127–134.

    OpenUrlPubMed
28. 28.↵
    1. Arumalla VK,
    2. Vani N,
    3. Ramarao J

    . Dose-dependent impacts on the diagnostic efficacies of atherogenic lipids in adult Indian smokers. J Clin Diagn Res 2011;5(7):1352–1355.

    OpenUrl
29. 29.↵
    1. Gaspard UJ,
    2. Gottal JM,
    3. van den Brûle FA

    . Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas 1995;21(3):171–178.

    OpenUrlCrossRefPubMedWeb of Science